Publications by authors named "L Agnello"

Scope: This study aimed to assess the antioxidant, anti-inflammatory, and acetylcholinesterase activities of fruiting bodies (FB) and mycelium (M) extracts of Morchella esculenta L. collected from various regions of Pakistan. The samples included Skardu fruiting body (SKFB) and mycelia Skardu (SKM), Malam Jaba fruiting body (MJFB) and Malam Jaba mycelia (MJM), Krair Mansehra fruiting body (KMFB) and Krair Mansehra mycelia (KMM), and Thandiani fruiting body (TFB) and Thandiani mycelia (TM).

View Article and Find Full Text PDF

Introduction: Neurofilament light chain (NfL) is one of the most important biomarkers in the field of clinical neurochemistry. Several analytical methods have been developed in the last decade. Recently, Fujirebio introduced a ready-to-use assay kit for measuring NfL levels in the cerebrospinal fluid (CSF) on the fully automated LUMIPULSE G System.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the significance of antinuclear antibodies (ANA) patterns in patients with liver diseases, focusing on autoimmune liver disease (AILD).
  • - Out of 396 patients tested, 33% were diagnosed with AILD, predominantly autoimmune hepatitis (AIH); specific ANA patterns showed varied prevalence among different liver diseases.
  • - The results indicate that certain ANA patterns (like AC1 for AIH and AC21 for primary biliary cholangitis) correlate strongly with specific liver conditions, suggesting their potential importance in clinical diagnosis.
View Article and Find Full Text PDF

Alzheimer's disease (AD) is the most common neurodegenerative disorder and a leading cause of dementia. One major challenge for clinicians is accurately assessing the rate of disease progression (RoP) early in the diagnostic process, which is crucial for patient management and clinical trial stratification. This study evaluated the role of cerebrospinal fluid biomarkers-Aβ42, t-Tau, pTau, Neurogranin (Ng), and Neurofilament light-chain (NF-L)-in predicting RoP at the time of AD diagnosis.

View Article and Find Full Text PDF